Hematopoietic stem cell transplantation in patients with severe combined immunodeficiency: A single-center experience

Basit Öğe Kaydı
dc.authorid0000-0002-4551-5433
dc.authorid0000-0002-9710-8653
dc.authorid0000-0002-0476-5452
dc.authorid0000-0002-9688-5223
dc.authorid0000-0002-7129-5024
dc.authorid0000-0001-8489-7449
dc.contributor.authorNepesov, Serdar
dc.contributor.authorYaman, Yöntem
dc.contributor.authorElli, Murat
dc.contributor.authorBayram, Nihan
dc.contributor.authorÖzdilli, Kürşat
dc.contributor.authorKıykım, Ayça
dc.contributor.authorAnak, Sema
dc.date.accessioned2022-08-24T11:28:29Z
dc.date.available2022-08-24T11:28:29Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.description.abstractObjective: The aim of this study was to determine the factors affecting outcomes in patients who underwent hematopoietic stem cell transplantation (HSCT) with the diagnosis of severe combined immunodeficiency (SCID). Furthermore, our aim is to share our singlecenter experience of HSCT among SCID patients. Materials and Methods: The data of patients who underwent HSCT with the diagnosis of SCID between January 2014 and January 2021 in the pediatric bone marrow transplant unit of Istanbul Medipol University were retrospectively analyzed. Demographic and clinical data, treatment regimens, donor source, type of transplantation, pre- and post-transplantation infections, and complications were evaluated. Results: Among fifteen patients who underwent HSCT, 5 (33%) were female. The mean age at diagnosis was 3 months (1-6 months), and at transplantation 6 months (3-10 months). The mean time from diagnosis to transplantation was 3 months (2-9 months). There was a history of consanguineous marriage in thirteen (87%) and sibling death in eight (53%) cases. As donors, six (40%) were siblings and five (33%) were unrelated, while four (27%) patients underwent haploid transplantation. Four (27%) patients died during the first 100 days of transplantation. The median follow-up period was 23 months (9-61 months). Overall survival probability was calculated as 73%. Conclusion: SCID should be considered as an emergency in pediatrics. Devastating complications, including severe organ damage, lifethreatening infections, and even death, could appear in case of diagnostic delay. HSCT is a currently available curative treatment option. Subjects with a confirmed diagnosis should be referred to the appropriate bone marrow transplant center and treated as soon as possible.
dc.identifier.citationNepesov, S., Yaman, Y., Elli, M., Bayram, N., Özdilli, K., Kıykım, A. ... Anak, S. (2022). Hematopoietic stem cell transplantation in patients with severe combined immunodeficiency: A single-center experience. Experimed, 12(1), 24-28. http://doi.org/10.26650/experimed.2022.1077058
dc.identifier.doi10.26650/experimed.2022.1077058
dc.identifier.endpage28
dc.identifier.issn2667-5846
dc.identifier.issue1
dc.identifier.scopusqualityN/A
dc.identifier.startpage24
dc.identifier.urihttp://doi.org/10.26650/experimed.2022.1077058
dc.identifier.urihttps://hdl.handle.net/20.500.12511/9666
dc.identifier.volume12
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.institutionauthorNepesov, Serdar
dc.institutionauthorYaman, Yöntem
dc.institutionauthorElli, Murat
dc.institutionauthorBayram, Nihan
dc.institutionauthorÖzdilli, Kürşat
dc.institutionauthorAnak, Sema
dc.language.isoen
dc.publisherIstanbul University
dc.relation.ispartofExperimeden_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectBone Marrow Transplantation
dc.subjectChildren
dc.subjectSevere Combined Immunodeficiency
dc.titleHematopoietic stem cell transplantation in patients with severe combined immunodeficiency: A single-center experience
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Nepesov-Serdar-2022.pdf
Boyut:
79.63 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu